Low-immunogenicity cell for expressing MCL1 and preparation method of low-immunogenicity cell
通过在干细胞中过表达MCL1基因并敲除B2M和CIITA基因,降低MHC-I和MHC-II的表达,解决了移植细胞免疫不相容和免疫排斥的问题,实现了低免疫原性多能干细胞的逃逸效果。
CN119662543APending Publication Date: 2025-03-21XELLSMART BIOMEDICAL (SUZHOU) CO LTD
43 Cites 0 Cited by
Patent Information
- Application Number
- CN202411318363.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-09-20
- Filing Date
- 2024-09-20
- Publication Date
- 2025-03-21
AI Technical Summary
Technical Problem
The prior art is difficult to effectively solve the immune incompatibility and immune rejection problems encountered by transplanted allofunctional cells in clinical applications.
Method used
By overexpressing the MCL1 gene in stem cells and combining knockout of the B2M and CIITA genes, the expression of MHC-I and MHC-II is reduced, thereby reducing or escaping the recognition and attack of the immune system.
Benefits of technology
Low immunogenic pluripotent stem cells are achieved, capable of escaping the attacks of T cells, NK cells and macrophages, while retaining the key biological functions of stem cells.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention provides a low-immunogenicity cell for expressing MCL1 and a preparation method of the low-immunogenicity cell. The low-immunogenicity pluripotent cell can significantly reduce or escape the recognition and attack of an immune system, especially the attack of T cells, natural killer cells, macrophages and ADCC, without changing the updating and differentiation characteristics of stem cells.
Need to check novelty before this filing date? Find Prior Art